Insitro's AI speeds up clinical trials for drug discovery

Daphne Koller, CEO of AI biotech Insitro, is leveraging artificial intelligence to accelerate the clinical trial process for drug discovery. Her work aims to make drug development faster and more efficient, ultimately bringing new treatments to patients sooner. The focus is on using AI to better predict how compounds will behave, which impacts future treatments for various body systems.